Bayer AG has confirmed that of the three projects in its Factor XIa program, the full focus is now on the oral treatment asundexian, ahead of two partnered therapies – fesomersen and osocimab – which had also shown potential in mid-stage trials.
Bayer Goes All In With Asundexian And Pulls Two Other Factor XIa Projects
Potential Xarelto Successor Prioritized
Despite promising mid-stage data for the Ionis-partnered fesomersen and osocimab, licensed from Aronora, the German major has plumped for asundexian as the priority compound for its Factor XIa efforts.

More from Earnings
As drugmakers update investors on first quarter financial performance, uncertainty around global trade and US regulatory oversight is likely to dominate discussions.
Sector-specific tariffs, including on pharmaceuticals, could be announced as early as this week.
Industry lobbied for pharmaceuticals to be exempt from Trump’s sweeping US tariffs and the effort appears to have paid off. J&J, Lilly and Merck & Co. even got shout outs.
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
More from Business
Chinese biopharma companies’ alliance strategies are transitioning from immediate cash needs to more strategic management of portfolios, as MNCs continue to hunt for derisked assets.
As drugmakers update investors on first quarter financial performance, uncertainty around global trade and US regulatory oversight is likely to dominate discussions.
Faced with Trump’s hostile tariff moves, the UK aims to speed up clinical trial start times to support its pharma sector and invest £600m in a new health data research service.